Their study appears in the June 11 issue of JAMA.
Insulin analogs are synthetic, molecularly altered versions of insulin that are equally effective in lowering glucose in T2D patients compared with human synthetic insulin, but much more expensive.
The researchers studied more than 123,000 patients with T2D who filled prescriptions for insulin between the years 2000 and 2010. They found that among privately insured adults in the United States, overall use of insulin among patients with T2D increased from 10% in year 2000 to 15% in 2010.
However, among those insulin users, the use of insulin analogs increased from 19% to 92% during this time. In addition, the median out-of-pocket cost per prescription for all types of insulin nearly doubled, increasing from $19 to $36 in the same time period. Although insulin analogs are supposed to reduce the risk of hypoglycemia, the authors did not find a significant decline in severe hypoglycemic events requiring a hospital visit.
“Not all patients with type 2 diabetes mellitus are likely to prefer or benefit from insulin analogs over human insulin preparations,” said first author Dr. Kasia Lipska, instructor in the Section of Endocrinology at Yale School of Medicine and Yale Center for Clinical Investigation scholar. She adds, “The rapid rate of adoption in the absence of large differences in advantages and disadvantages suggests that these decisions may have been driven by factors other than patient preference. In order to contain healthcare costs, decisions to use more expensive insulin should be made by informed patients and providers, and driven by convincing data about the benefits, harms, and tradeoffs.”
Other authors are Dr. Joseph Ross of Yale School of Medicine; Dr. John Yudkin of University College London; David Beran of the University of Geneva; and Holly Van Houten and Nilay Shah of the Mayo Clinic.
This study was supported by a grant from the Agency for Healthcare Research and Quality.
(Image via Shutterstock)